Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Another good find ... more of the same signposting of INF's, and Monk et al used in references:
“Our data revealed increased interferon resistance in SARS-CoV-2 variants of concern, suggesting a significant but underappreciated role for innate immunity in driving the next phase of the COVID-19 pandemic.”
“A recent Phase III clinical trial demonstrating that IFNß may not have therapeutic benefits in vivo (13) could be due to the late timing of administration among hospitalized/severely ill patients, cotreatment with glucocorticoids such as dexamethasone that directly antagonize IFN signaling.”
“Numerous studies have shown that IFNs are important for host defense against SARS-CoV-2.”
“Overall, the present study suggested a role for the innate immune response in driving the evolution of SARS-CoV-2 that could have practical implications for IFN-based therapies.”
Daily Covid cases reach record 351,000 in UK, latest estimates show
https://f7td5.app.goo.gl/p1i4QY
Sent via @updayUK
... One long year ago we had left June behind and were looking to September, then November and the waiting game was slowly reducing from months, to weeks and approaching February we were down to days if not hours awaiting 'imminent' deliverance. The hardest thing is gearing that timescale expectation back up. Personally, I remain just as confident of the end game (not the crazy values previously attributed, but nevertheless a good return of few multiples of the last placement) but actually re-setting the time clock is, I believe, necessary to retain sanity and manage the timescale expectations here. We all know this, and easily say it to ourselves (and those in our lives we need to convince) but we need (imho) have to 'live' by that. Take a good step back, count to ten, breathe and enjoy what you have around you, and keep the faith ... but maybe just keep it a bit further back from 'front & centre'. We are investors, not CEO's, CFO's, COO's, CCO's but those who attended the AGM presented a strong voice for all of us ... so let those we have handsomely invested in to take the stress and maintain the hourly, daily, weekly, monthly focus that success will require. The world will turn, and we will get there. Have a great week and GLA.
Such a shame after an AGM that most, if not all, were happy with ... I just wish people would take care when criticising what others write, despite analysing the language actually used, rather than jumping when the general tone is either positive or negative and at odds with the reader. I see knee jerks all over the place and when I go to read and ascertain why, I see language like, "could", "if", "my opinion" .. yet some take exception as if the comments made are being given as, "fact". We all drink, but our glasses will never hold the same amount so we should accept some will be half full more or less than others. All opinions are equally valid but personal attacks should be below most of us surely?
A bit late in adding thanks, but have just read every word on way home after 6 flights in 7 days and well knackered, but full of excitement, and admiration for fellow PI's who have put the summary together. I feel you may have just done another service by hopefully galvanising our band of SNG'r's despite the wide and varying views often expressed. I will certainly sleep well and may even try to summarise to Mrs A !
Just adding thanks, whilst inbetween flights, to all those taking the time to confer and get notes typed up. Really wanted to be there, so not laziness on my part so, like others on here, very grateful for the effort that is going on to give us the PI view.
Quite frustrating not being able to attend. Did get the letter through but had to take a job offer so sitting bored in an Indonesian airport lounge. Any updates gratefully received to relieve the layover boredom. Are you in the 'not there' club ?
From Monkey Pox to a resurgence of Avian Flu and upward trends in COVID cases we may be entering an interesting time that will potentially make for some deft PR and marketing.
https://www.dailyrecord.co.uk/news/scottish-news/bird-flu-scotland-species-extinction-27192754
Thanks (Fazer 1) for yet another positive article. I tend to find these financial and Pharma-related articles /reports help me to support what, for me, is otherwise just wishful-thinking for the future of SNG. It does seem that two messages are coming out fairly strong in these areas that, big-fish Pharma are looking to snap up smaller ones, and INF's are being universally lauded for their efficacy and benefits. SNG are hopefully on mission to make themselves suitable 'bait', and successfully marry these two together.
Very interesting paper for two (possibly connected) reasons.
1. that it seems, given its origin, to be a reasonable 'dumbed-down' or laymen's explanation rather than something for the scientific community, and
2. that it comes out now ... maybe suggestive of FDA future plans requiring some pro-active public messaging in advance?
I accept of course this is very much a glass-half-full view.
Footnote 71 (Monk et al reference)
“However, a small randomized controlled trial in a similar population of hospitalized patients with COVID-19 found that treatment with aerosolized IFNß1a led to more rapid recovery compared with placebo71”
Record 2 million people in UK estimated to have long Covid
https://f7td5.app.goo.gl/katKUr
Sent via @updayUK
As for the current SP, simply we are where we are. Having notionally 'benefitted' from a £2 SP on anticipation of Sprinter P3, the reverse is now true post 21 Feb with a very pessimistic £0.25 SP. Whilst, Fincap may be sitting on the fence in one sense, I would also expect that (post A2P2 .. with expected good results) the previous anticipation level, particularly with a confirmed A2P3 (or similar) could quickly return. In short my expectations (based on the above) are for a hopeful return to at nearer £2 later this year, with any earlier offer <£2 being roundly rejected (by Poly at least). Then, as we get closer towards expected results of an A2P3 (or similar c. Q1 2023), an offer closer to £4-5 may be likely to prevent paying a lot more (£5-10) post A2P3 (good) results. All wishing thinking and dreaming at this stage of course.
... to de-risk investor stress, frustration and patience deterioration. Well, that's what I planning alongside the garden and whatever Mrs A has planned for me.
We're in a dip - there's no doubt, so just throwing it out there that we could all possibly benefit (individually and collectively) from a recalibration of anticipation and expectation levels in terms of timescale. I say 'timescale' as I believe that most (if not all) openly, or privately, believe this will come good - it's the timescales that are killing us. So, stay physically and mentally healthy to fully enjoy when it comes ... and ... breath.
The upcoming 12.00 webcast aside, it would seem the question of A2P2 results keep percolating and rising to the top of the SNG mystery's list.
I don't think (?) we have had a suggestion so far that seems to explain the delay. Today we are told 'summer' so there seems no change to the 'by June' suggestion I recall from earlier. This, then, seems to be the only consistent expectation, other than knowing we 'were' progressing to (the now ceased) A2P3 ... and one of a very small number to achieve this. Whether the group was deemed too small to spend more USD$ on, and/or whether our very own P3 results spooked the US as to re-thinking the future, it does seem that a complete (ACTIV) re-write is under way over the pond. Could it simply be this change, with potentially many future $bn's at stake, that is keeping our results under wraps. A2P3 progression should signal that A2P2 results are (at worst) 'good'. The undoubted financial, certainly commercial and perhaps even political implications of what is to come next may just be all that it takes for our US cousins to sit on their/our data, until the they complete whatever the future holds for the next iteration of ACTIV or its upgrade. Whilst we can't quite understand the need to withhold data for so long, it may be that this is normal practice for the US ?
“We are now working in haste on discussions with platform trial organisers and investigators, as well as regulatory authorities, the pharmaceutical and biotech industry and government bodies to identify and establish the optimal method of conducting further trials to confirm these findings and move forward, not just for COVID-19, but also as a potential treatment for patients hospitalised due to a range of viruses including influenza, RSV, adenovirus, para-influenza and rhinoviruses.”